This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

DC cardioversion of atrial fibrillation

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

DC cardioversion requires a light general anaesthetic or sedation with intravenous diazepam; intubation is not usually required.

  • the DC shock is synchronized with an R wave on the electrocardiogram in order to reduce the chance of ventricular fibrillation
  • presence of two or more consecutive P waves after shock delivery is usually considered as an indication of successful DCC (1)

DC cardioversion may precipitate systemic emboli from intracardiac thrombus. To avoid thromboembolic events:

  • formal anticoagulation is required for at least three weeks before and four weeks after the cardioversion since
    • thrombi may form as soon as 48 hours after the onset of AF(2)
    • co-ordinated atrial activity may not resume for 2 weeks following cardioversion even if sinus rhythm is apparent on the ECG
  • prolonged anticoagulation is not needed when the arrhythmia has existed for less than 48 hours
    • no intracardiac thrombus is apparent on trans-oesophageal echocardiography (3)

The use of DC cardioversion is

  • recommended acutely in patients who are haemodynamically unstable
  • considered electively in order to initiate a long-term rhythm control management strategy (1)

In patients who are haemodynamically stable and do not have severe underlying heart disease, outpatient/ambulatory DCC can be carried out (1)

The results of DC cardioversion in patients with chronic atrial fibrillation indicate a high initial effectiveness but poor long-term effectiveness:

  • 70-90% patients with chronic atrial fibrillation will be converted to sinus rhythm by DC cardioversion
  • 60-75% of successfully cardioverted patients will revert to atrial fibrillation within one year

NICE state with respect to cardioversion (6)

  • for people having cardioversion for atrial fibrillation that has persisted for longer than 48 hours, offer electrical (rather than pharmacological) cardioversion
  • consider amiodarone therapy starting 4 weeks before and continuing for up to 12 months after electrical cardioversion to maintain sinus rhythm, and discuss the benefits and risks of amiodarone with the person.
  • for people with atrial fibrillation of greater than 48 hours' duration, in whom elective cardioversion is indicated
    • both transoesophageal echocardiography (TOE)-guided cardioversion and conventional cardioversion should be considered equally effective
    • a TOE-guided cardioversion strategy should be considered:
      • where experienced staff and appropriate facilities are available and
      • where a minimal period of precardioversion anticoagulation is indicated due to the person's choice or bleeding risks

  • in people with atrial fibrillation in whom the duration of the arrhythmia is greater than 48 hours or uncertain and considered for long-term rhythm control, delay cardioversion until they have been maintained on therapeutic anticoagulation for a minimum of 3 weeks
    • during this period offer rate control as appropriate

Notes:

  • DCC is contraindicated in patients with digitalis toxicity (1)
  • maintaining sinus rhythm after cardioversion
    • several class IA, IC and III drugs are effective in maintaining sinus rhythm but increase adverse events, including pro-arrhythmia, and disopyramide and quinidine are associated with increased mortality. The authors of a systematic review concluded that (5) any benefit on clinically relevant outcomes (embolisms, heart failure, mortality) remains to be established

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.